Combating radiophobia: a top priority for the further development of nuclear medicine Authors: Panagiotis Georgoulias, George Angelidis, Emmanouil Panagiotidis, Varvara Valotassiou, Ioannis Tsougos Published: 2026 The history of ionizing radiation in the universe spans from the early universe (the extreme, high-energy environment post-Big Bang) to the present day. Cosmic rays and the decay of radioactive isotopes have been the primary sources of natural ionizing radiation on Earth, contributing to background radiation. Human evolution occurred under continuous exposure to natural background radiation. Radiophobia represents the irrational, excessive fear of ionizing radiation, usually associated with a significant overestimation of radiation health risks (Hayes 2025). The term describes a public, collective reaction to perceived risks that are disproportionate to the actual risks associated with medical radiation exposures, as radiophobia is mainly a social phenomenon commonly linked to (intended or unintended) contamination incidents, such as the Hiroshima bombing or the Chernobyl accident. Although radiophobia is not a strictly clinical phobia, it can cause individually severe psychological distress, including high anxiety levels, depression, and avoidance behaviours - mainly refusing appropriate medical procedures and potentially leading to adverse medical outcomes. On the other hand, nuclear medicine has a widely established role in the diagnostic and therapeutic management of health disorders in various medical fields, particularly in oncology, cardiology, endocrinology, and neurology. By acting at a cellular level, diagnostic nuclear medicine applications provide unique functional information, often detecting diseases in their early stages when prognosis is significantly better. Furthermore, targeted radioactive treatments, such as radiodine (131I) therapy for thyroid cancer and lutetium-177 (177Lu) therapy for neuroendocrine tumours and metastatic castration-resistant prostate cancer, are available in current clinical practice, offering complete response, a better prognosis, or - at least - advanced quality of life to the patients. Given our clinical experience, most patients are seriously concerned about the impending radiation exposure, when referred for a nuclear medicine diagnostic procedure. These concerns are typically related to the common misconception that ‘’any and all radiation’’ is harmful, which is based on popular radiophobic beliefs, but also supported by the linear no-threshold (LNT) hypothesis (Scott 2025). This hypothesis was conceptualized during the 1950s by the extrapolation of high-dose exposure data (e.g. evidence from the atomic bomb Life Span Study) linearly down to the zero exposure point. According to the LNT model, any radiation exposure has a cancer risk and radiation exposures, experienced at different times, can be added to determine a cumulative effective dose. However, the application of the LNT model is supported by epidemiology studies only at high radiation exposures. Its applicability at low doses is significantly disputed, as there are no clinical - epidemiological data supporting the linear relationship between radiation dose and cancer risk at the low-dose region. On the contrary, other proposed models assume no health risk at low radiation exposures, including the threshold model, which claims that very small exposures are harmless, and the radiation hormesis model, which assumes that radiation at very small doses can be beneficial (Scott 2025). The adoption of the LNT model for radiation risk assessment was based on fruit fly experiments in which high radiation doses resulted in trans-generational phenotypic changes, claimed to occur due to gene mutations. However, current research evidence shows that the applicability of the LNT model at low doses remains debated within the scientific community (Scott 2025). Early genetic experiments in model organisms contributed to the development of the LNT hypothesis, although their direct applicability to human low-dose exposures has been questioned. Currently, cancer is considered a stochastic (probabilistic), long-term result of radiation exposure, and its likelihood of occurrence - but not severity - increases with dose. Population-averaged lifetime cancer risk estimates are often cited at approximately 5% per Sv (0.005% per mSv), based on epidemiological modelling (ICRP 2007). Interestingly, it is difficult to detect any effects of radiation exposure below 100 mSv. Nevertheless, national and international regulatory bodies, including the National Academies of Sciences, Engineering, and Medicine (NAS) Committee on the Biological Effects of Ionizing Radiation (BEIR), the National Council on Radiation Protection and Measurements (NCRP), and the International Commission on Radiological Protection (ICRP), continue to use the LNT model for radiation risk assessment, assuming that there is no threshold for radiation stochastic effects, and any exposure - no matter how small - carries some risk. On the other hand, a growing number of nuclear scientists argue that the application of the LNT model at low dose range is controversial, since there is no evidence of cancer risk at doses < 100 mSv. In most occasions, the use of the appropriate imaging modality can lead to definitive and timely diagnosis, guiding therapeutic interventions. On the contrary, patients who refrain from radionuclide diagnostic techniques, due to radiophobia, may face potential real harm from a misdiagnosis. It is crucial to perform the diagnostic investigation of our patients based on the indications (and contraindications) of each modality, taking into account the advantages and disadvantages of the available techniques, independently of low-dose radiophobia concerns (Angelidis et al. 2020). For example, in patients with known or suspected coronary artery disease (CAD), stress echocardiography is promoted in clinical practice, having the absence of radiation exposure as its main advantage. Nevertheless, it is a highly operator-dependent technique, a characteristic that should limit its use in centres with adequate experience in the field. In addition, this technique requires adequate acoustic windows, and the image quality can be sub-optimal in obese patients and those with pulmonary disease. On the other hand, nuclear cardiology techniques are significantly less operator-dependent and of significantly higher diagnostic and prognostic value in detecting myocardial ischemia and viability. In particular, modern imaging systems, such as cadmium-zinc-telluride (CZT) and positron emission tomography (PET) cameras, also enable accurate quantification of myocardial blood flow, serving as superior tools for CAD investigation and microvascular dysfunction identification. In addition, taking into account the minimal effect (if any) of doses below 100 mSv, radiation exposure should not represent a reason for not undergoing myocardial perfusion imaging in this patients’ group, particularly in cases with potential sub-optimal results in stress echocardiography due to patient characteristics. Furthermore, several radionuclide therapies can be beneficial for patients suffering from both benign and malignant disorders. For example, when antithyroid medications are proving to be ineffective or are associated with serious side effects, radioiodine (131I) therapy represents a highly effective and safe option for the management of hyperthyroidism due to Grave’s disease, or toxic thyroid nodules (Campennì et al. 2023). Radioiodine is administered on an outpatient basis, and leads to complete response in > 80% of the patients after a single dose (15 mCi). However, a significant part of the patients prefer to undergo surgery, as a result of radiophobia. Obviously, thyroidectomy is potentially associated with both surgical and anesthetic complications, including temporary and persistent hypoparathyroidism, hypocalcemia, post-operative bleeding, and vocal cord palsy. Notably, the avoidance of these complications may be even more important in older patients, or individuals with concurrent disorders. Finally, in the era of the emerging precision medicine, theragnostics provides a combination of diagnostic investigation and targeted treatment in oncology patients, using paired radiopharmaceuticals for diagnostic and therapeutic purposes (Smith 2025). Interestingly, this approach has been associated with both reduced side effects and improved outcomes for malignancies, such as thyroid cancer, prostate cancer, and neuroendocrine tumors. To conclude, despite the well-established role of nuclear medicine in the management of various health disorders, the dramatized presentation of radiation hazards due to previous major events, such as the Hiroshima-Nagasaki bombing and Chernobyl accident, has contributed to the persistent patient anxiety over radiation safety. Nevertheless, by promoting public understanding of the peaceful and beneficial uses of radiation in the medical field, nuclear medicine can be featured as a symbol of healing rather than fear. It is important to emphasize that the ‘’real danger’’ associated with low-dose radiation exposure is highly controversial, and surely not supported by the available clinical - epidemiological evidence. Consequently, not only our scientific societies but also the nuclear medicine scientists should be clear as far as radiation exposure concerns in clinical routine, highlighting that our specialty represents the ‘’bright side of the moon’’. Acknowledgements Not applicable. Author contributions The first draft of the manuscript was written by PG and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript. Funding Not applicable. Data availability Not applicable. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Not applicable.